355 related articles for article (PubMed ID: 8277200)
21. [Safety and immunogenicity of split vaccines of influenza viruses].
Zhu CL; Fang HH; Zhu FC; Wang YQ; Wu XL; Xue FB; Shen YJ; Lian JZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):207-9. PubMed ID: 15640848
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
Belshe RB; Gruber WC; Mendelman PM; Cho I; Reisinger K; Block SL; Wittes J; Iacuzio D; Piedra P; Treanor J; King J; Kotloff K; Bernstein DI; Hayden FG; Zangwill K; Yan L; Wolff M
J Pediatr; 2000 Feb; 136(2):168-75. PubMed ID: 10657821
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.
Brady RC; Jackson LA; Frey SE; Shane AL; Walter EB; Swamy GK; Schlaudecker EP; Szefer E; Wolff M; McNeal MM; Bernstein DI; Steinhoff MC
Vaccine; 2018 Jul; 36(31):4663-4671. PubMed ID: 29961606
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.
Gruber WC; Belshe RB; King JC; Treanor JJ; Piedra PA; Wright PF; Reed GW; Anderson E; Newman F
J Infect Dis; 1996 Jun; 173(6):1313-9. PubMed ID: 8648202
[TBL] [Abstract][Full Text] [Related]
26. Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.
King JP; McLean HQ; Meece JK; Levine MZ; Spencer SM; Flannery B; Belongia EA
Vaccine; 2018 Feb; 36(9):1214-1219. PubMed ID: 29395525
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
[TBL] [Abstract][Full Text] [Related]
29. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
Talaat KR; Karron RA; Callahan KA; Luke CJ; DiLorenzo SC; Chen GL; Lamirande EW; Jin H; Coelingh KL; Murphy BR; Kemble G; Subbarao K
Vaccine; 2009 Jun; 27(28):3744-53. PubMed ID: 19464558
[TBL] [Abstract][Full Text] [Related]
30. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
[TBL] [Abstract][Full Text] [Related]
31. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity].
Slepushkin AN; Rudenko LG; Kendal AP; Monto AS; Beliaev AL; Burtseva EI; Grigor'eva EP; Obrosova-Serova NP; Ivanova VT; Bragina VE
Vopr Virusol; 1994; 39(3):129-31. PubMed ID: 8091754
[TBL] [Abstract][Full Text] [Related]
32. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.
Bernstein DI; Yan L; Treanor J; Mendelman PM; Belshe R;
Pediatr Infect Dis J; 2003 Jan; 22(1):28-34. PubMed ID: 12544405
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
[TBL] [Abstract][Full Text] [Related]
34. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
[TBL] [Abstract][Full Text] [Related]
35. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.
Ohmit SE; Victor JC; Rotthoff JR; Teich ER; Truscon RK; Baum LL; Rangarajan B; Newton DW; Boulton ML; Monto AS
N Engl J Med; 2006 Dec; 355(24):2513-22. PubMed ID: 17167134
[TBL] [Abstract][Full Text] [Related]
36. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults.
Keitel WA; Couch RB; Quarles JM; Cate TR; Baxter B; Maassab HF
J Infect Dis; 1993 Feb; 167(2):305-11. PubMed ID: 8421165
[TBL] [Abstract][Full Text] [Related]
37. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial.
Alexandrova GI; Budilovsky GN; Koval TA; Polezhaev FI; Garmashova LM; Ghendon YuZ ; Romanova YR; Smorodintsev AA
Vaccine; 1986 Jun; 4(2):114-8. PubMed ID: 3524050
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
[TBL] [Abstract][Full Text] [Related]
39. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
40. Influenza vaccines in children.
Neuzil KM; Edwards KM
Semin Pediatr Infect Dis; 2002 Jul; 13(3):174-81. PubMed ID: 12199613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
